Auxergen Intern Harrison Chang Publishes a Comprehensive Review on Tea Polyphenols and COVID-19 in Current Issues in Molecular Biology
Baltimore, MD – April 6, 2026 — Auxergen Inc. is proud to announce the publication of “Tea Polyphenols in the COVID-19 Era: Mechanistic Insights and Translational Challenges” in the journal Current Issues in Molecular Biology (https://www.mdpi.com/1467-3045/48/4/379).
Lead author Harrison Chang, a tenth-grade high school student and intern at Auxergen, provides a critical chemo-biological evaluation of how bioactive compounds found in tea, like EGCG and theaflavins, interact with the SARS-CoV-2 virus and the human immune system.
Key Research Highlights
The review synthesizes emerging evidence on the multi-targeted potential of tea-derived nutraceuticals to manage COVID-19 (Figure 1) and its long-term effects:
- Inhibition of Viral Entry and Replication: The paper details how tea polyphenols may block the interaction between the viral “spike” protein and human ACE2 receptors. Furthermore, it highlights their ability to inhibit essential viral enzymes like the 3CLpro protease and RdRp polymerase, effectively blocking the virus’s ability to replicate.
- Taming the “Cytokine Storm”: Beyond direct antiviral action, the paper explores the immunomodulatory effects of catechins, which help reduce the overproduction of pro-inflammatory cytokines (such as IL-6 and TNF-α) that drive severe lung injury.
- Addressing the “Long COVID” Gap: The authors investigate the potential for these compounds to aid tissue repair and reduce chronic inflammation, offering a possible nutritional strategy for patients suffering from post-acute sequelae of SARS-CoV-2 (PASC).
- Navigating Translational Hurdles: A critical focus of the paper is the “bioavailability bottleneck,” which is the challenge of ensuring these compounds reach effective concentrations in the lungs via oral consumption, and the potential for new delivery methods like nano-formulations or aerosolized treatments.
Figure 1. Proposed antiviral targets of tea polyphenols across the coronavirus life cycle. Numerical labels (1–5) denote specific mechanistic checkpoints targeted by tea polyphenols, ranging from initial viral entry to progeny virion maturation.
“Our goal at Auxergen is to bridge the gap between clinical science and phytochemical biology,” says Dr. Ting-Yu Yeh, Chief Scientific Officer at Auxergen. “Tea polyphenols show promise in blocking viral mechanisms for infectious diseases like COVID-19. We must continue innovating along the natural product pipeline, at the interplay of human therapeutics and plant science.”
###
About Auxergen
Auxergen is a multinational biotechnology company headquartered in Baltimore, Maryland, focused on developing advanced therapeutics and diagnostics in virology, genomics, and microbial engineering. With a global team of experts, Auxergen is committed to translating groundbreaking research into real-world solutions for infectious diseases and beyond. For more information, visit www.auxergen.com.
Media Contact
Auxergen
Michael Feehley
Email: michael@auxergen.com
Phone: (443)-929-9757